A novel compound, NP-184, inhibits the vascular endothelial growth factor induced angiogenesis

European Journal of Pharmacology

Volumn 630, Issue 1-3, 2010, Pages 53-60

  Lin, Kuan Ting ^a   Lien, Jin Cherng ^b   Chung, Ching Hu ^c   Kuo, Sheng Chu ^b   Huang, Tur Fu ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Angiogenesis; Benzimidazole; HUVEC; VEGF

Indexed keywords

2 (5 METHYL 2 FURYL)BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NP 184; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG STRUCTURE; ENDOTHELIUM CELL; ENZYME ACTIVATION; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION INHIBITION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; VASCULAR RING;

ANGIOGENESIS INHIBITORS; BENZIMIDAZOLES; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77649181622     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.12.036     Document Type: Article

References (41)

1. Alavi A., Hood J.D., Frausto R., Stupack D.G., Cheresh D.A. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003, 301:94-96.
2. Alladina S.J., Song J.H., Davidge S.T., Hao C., Easton A.S. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2. J. Vasc. Res. 2005, 42:337-347.
3. Berra E., Milanini J., Richard D.E., Le Gall M., Vinals F., Gothie E., Roux D., Pages G., Pouyssegur J. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem. Pharmacol. 2000, 60:1171-1178.
4. Bond M., Fabunmi R.P., Baker A.H., Newby A.C. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett. 1998, 435:29-34.
5. Brill A., Elinav H., Varon D. Differential role of platelet granular mediators in angiogenesis. Cardiovasc. Res. 2004, 63:226-235.
6. Bussolino F., Mantovani A., Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem. Sci. 1997, 22:251-256.
7. Caine G.J., Lip G.Y., Stonelake P.S., Ryan P., Blann A.D. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb. Haemost. 2004, 92:185-190.
8. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69(Suppl 3):4-10.
9. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
10. Cee V.J., Cheng A.C., Romero K., Bellon S., Mohr C., Whittington D.A., Bak A., Bready J., Caenepeel S., Coxon A., Deak H.L., Fretland J., Gu Y., Hodous B.L., Huang X., Kim J.L., Lin J., Long A.M., Nguyen H., Olivieri P.R., Patel V.F., Wang L., Zhou Y., Hughes P., Geuns-Meyer S. Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase. Bioorg. Med. Chem. Lett. 2009, 19:424-427.
11. Dimmeler S., Zeiher A.M. Endothelial cell apoptosis in angiogenesis and vessel regression. Circ. Res. 2000, 87:434-439.
12. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004, 9(Suppl 1):2-10.
13. Fidler I.J., Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994, 79:185-188.
14. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
15. Folkman J. Clinical applications of research on angiogenesis. N. Engl. J. Med. 1995, 333:1757-1763.
16. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 2007, 6:273-286.
17. Gerber H.P., Dixit V., Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. 1998, 273:13313-13316.
18. Grosjean J., Kiriakidis S., Reilly K., Feldmann M., Paleolog E. Vascular endothelial growth factor signalling in endothelial cell survival: a role for NFkappaB. Biochem. Biophys. Res. Commun. 2006, 340:984-994.
19. Gupta K., Kshirsagar S., Li W., Gui L., Ramakrishnan S., Gupta P., Law P.Y., Hebbel R.P. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp. Cell Res. 1999, 247:495-504.
20. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
21. Hori A., Imaeda Y., Kubo K., Kusaka M. Novel benzimidazole derivatives selectively inhibit endothelial cell growth and suppress angiogenesis in vitro and in vivo. Cancer Lett. 2002, 183:53-60.
22. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
23. Italiano J.E., Richardson J.L., Patel-Hett S., Battinelli E., Zaslavsky A., Short S., Ryeom S., Folkman J., Klement G.L. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008, 111:1227-1233.
24. Jaffe E.A., Nachman R.L., Becker C.G., Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 1973, 52:2745-2756.
25. Karkkainen M.J., Petrova T.V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000, 19:5598-5605.
26. Kirk R.I., Sanderson M.R., Lerea K.M. Threonine phosphorylation of the beta 3 integrin cytoplasmic tail, at a site recognized by PDK1 and Akt/PKB in vitro, regulates Shc binding. J. Biol. Chem. 2000, 275:30901-30906.
27. Kubota Y., Kleinman H.K., Martin G.R., Lawley T.J. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J. Cell Biol. 1988, 107:1589-1598.
28. Leavesley D.I., Schwartz M.A., Rosenfeld M., Cheresh D.A. Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J. Cell Biol. 1993, 121:163-170.
29. Liu C.Z., Hur B.T., Huang T.F. Measurement of glycoprotein IIb/IIIa blockade by flow cytometry with fluorescein isothiocyanate-conjugated crotavirin, a member of disintegrins. Thromb. Haemost. 1996, 76:585-591.
30. Liu J., Zhan M., Hannay J.A., Das P., Bolshakov S.V., Kotilingam D., Yu D., Lazar A.F., Pollock R.E., Lev D. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis. Mol. Cancer Res. 2006, 4:803-810.
31. Morales-Ruiz M., Fulton D., Sowa G., Languino L.R., Fujio Y., Walsh K., Sessa W.C. Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. Circ. Res. 2000, 86:892-896.
32. Mukhopadhyay D., Nagy J.A., Manseau E.J., Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium. Cancer Res. 1998, 58:1278-1284.
33. Mukhopadhyay T., Sasaki J., Ramesh R., Roth J.A. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin. Cancer Res. 2002, 8:2963-2969.
34. Nicolai E., Goyard J., Benchetrit T., Teulon J.M., Caussade F., Virone A., Delchambre C., Cloarec A. Synthesis and structure-activity relationships of novel benzimidazole and imidazo[4, 5-b]pyridine acid derivatives as thromboxane A2 receptor antagonists. J. Med. Chem. 1993, 36:1175-1187.
35. Nicosia R.F., Ottinetti A. Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: a comparative study of angiogenesis in Matrigel, collagen, fibrin, and plasma clot. In Vitro Cell Dev. Biol. 1990, 26:119-128.
36. Passaniti A., Taylor R.M., Pili R., Guo Y., Long P.V., Haney J.A., Pauly R.R., Grant D.S., Martin G.R. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 1992, 67:519-528.
37. Scappaticci F.A. Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol. 2002, 20:3906-3927.
38. Scappaticci F.A., Skillings J.R., Holden S.N., Gerber H.P., Miller K., Kabbinavar F., Bergsland E., Ngai J., Holmgren E., Wang J., Hurwitz H. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl. Cancer Inst. 2007, 99:1232-1239.
39. Sebolt-Leopold J.S., Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 2004, 4:937-947.
40. Shono T., Ono M., Izumi H., Jimi S.I., Matsushima K., Okamoto T., Kohno K., Kuwano M. Involvement of the transcription factor NF-kappaB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol. Cell. Biol. 1996, 16:4231-4239.
41. Won M.S., Im N., Park S., Boovanahalli S.K., Jin Y., Jin X., Chung K.S., Kang M., Lee K., Park S.K., Kim H.M., Kwon B.M., Lee J.J. A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway. Biochem. Biophys. Res. Commun. 2009, 385:16-21.